Alphabet's
Verily unit launches study to track health data
Send a link to a friend
[April 20, 2017] (Reuters)
- Verily, Alphabet Inc's life sciences
business, said it was launching a four-year study with about 10,000
participants to understand how people transition from being healthy to
becoming sick, and to identify additional risk factors for diseases.
|
Verily is partnering with Duke University and Stanford Medicine in
the United States to enroll participants from varying backgrounds at
sites in California and North Carolina within the next few months.
The study is the first initiative of Project Baseline, a broader
effort to develop a reference, or a "baseline", for what "health"
refers to.
The study will collect data, as well as biological samples such as
blood and saliva.
The sites will gather data from participants through repeat clinical
visits, a wristwatch that monitors heart rate and activity levels,
as well as participation in surveys and polls.

"The Project Baseline study has the opportunity to significantly
influence our current body of knowledge by better understanding the
indicators of wellness," Nancy Brown, chief executive officer of the
American Heart Association, said in a statement.
"The outcome of this study could inspire a new generation of tools
that are geared towards disease prevention versus just diagnosis and
treatment," she added.
Beyond this initial study, the project will also test and develop
new tools and technologies to access and organize health
information.
In September, pharmaceutical company Sanofi SA and Verily unveiled a
$500 million investment in a joint venture which combined devices
with services to improve diabetes care, an example of growing ties
between the pharmaceutical and technology sectors.
[to top of second column] |

Verily also has several other medical projects in the works,
including the development of a smart contact lens in partnership
with Swiss drugmaker Novartis AG that has an embedded glucose sensor
to help monitor diabetes.
(Reporting by Anya George Tharakan in Bengaluru; Editing by Shounak
Dasgupta)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.

 |